Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and accessibility. What’s keeping the pills from taking off?

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Rybelsus (semaglutide) is a prescription drug that’s used to manage blood sugar levels in people with type 2 diabetes. This drug can interact with other medications, such as levothyroxine ...

Rybelsus (semaglutide) can cause side effects that range from mild to serious. More common side effects include constipation and diarrhea. If side effects from Rybelsus become difficult to ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6% and also help people lose up to 16 ...

FAT jabs like Ozempic are set to get the seal of approval from the World Health Organisation (WHO). This would back the use ...

Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government ...

A decision is expected in the fourth quarter of 2025.

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Ozempic. Wegovy. Rybelsus. What do these medications have in common? They all contain the active ingredient semaglutide.

NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...